Children under two years old with signs of atopic dermatitis have an increased risk of developing asthma and food allergies, researchers report in JAMA Pediatrics. And, young children with both early onset atopic dermatitis and a food allergy, have a “very high risk” of developing asthma or allergic rhinitis.
EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.
Ingredients used in topical products used to relieve atopic dermatitis in children might put those patients at higher risk for contact dermatitis.
NIH investigators find that Staphylococcus epidermidis is predominant in less severe cases, while Staphylococcus aureus is associated with patients who have more severe disease.
Nitric oxide-releasing cream that targets IL-17 moving toward clinical trials.
An experimental drug designed to control itching in people with moderate-to-severe AD shows promise in early trial.
A new study shows that mutations in the gene CARD11 are associated with severe atopic disease.
In early research, subcutaneous nemolizumab significantly reduced pruritus in moderate-to-severe atopic dermatitis adult patients.
Patients with severe atopic dermatitis who have lower serum vitamin D levels have a high sensitivity to house dust mites which can aggravate their condition, a new study shows.
Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.